Sökresultat - Richard D. DiMarchi

Förfina resultatet
  1. 1
    Fibroblast growth factor 21 night watch: advances and uncertainties in the field

    Fibroblast growth factor 21 night watch: advances and uncertainties in the field av Alexei Kharitonenkov, Richard D. DiMarchi

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  2. 2
    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety

    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety av Rongjun He, Brian Finan, John P. Mayer, Richard D. DiMarchi

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  3. 3
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges av Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  4. 4
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists av Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  5. 5
    Optimization of the Native Glucagon Sequence for Medicinal Purposes

    Optimization of the Native Glucagon Sequence for Medicinal Purposes av Joseph R. Chabenne, Maria A. DiMarchi, Vasily M. Gelfanov, Richard D. DiMarchi

    Publicerad 2010
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology av Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  7. 7
    Insulin analogues and their potential in the management of diabetes mellitus

    Insulin analogues and their potential in the management of diabetes mellitus av Geremia B. Bolli, Richard D. Di Marchi, G. D. Park, Stig Pramming, Veikko A Koivisto

    Publicerad 1999
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  8. 8
    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis

    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis av Joseph P. Tiano, Chandra R. Tate, Bin Yang, Richard D. DiMarchi, Franck Mauvais‐Jarvis

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes av Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, Jonathan E. Campbell

    Publicerad 2018
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  10. 10
    The metabolic actions of glucagon revisited

    The metabolic actions of glucagon revisited av Kirk M. Habegger, Kristy M. Heppner, Nori Geary, Timothy J. Bartness, Richard D. DiMarchi, Matthias H. Tschöp

    Publicerad 2010
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  11. 11
    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment

    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment av Shravan Babu Girada, Ramya S. Kuna, Shilpak Bele, Zhimeng Zhu, N.R. Chakravarthi, Richard D. DiMarchi, Prasenjit Mitra

    Publicerad 2017
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice av Kristy M. Heppner, Sarah Marks, Jenna Holland, Nickki Ottaway, David L. Smiley, Richard D. DiMarchi, Diego Pérez–Tilve

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    Peptide lipidation stabilizes structure to enhance biological function

    Peptide lipidation stabilizes structure to enhance biological function av Brian Ward, Nickki Ottaway, Diego Pérez–Tilve, Dejian Ma, Vasily M. Gelfanov, Matthias H. Tschöp, Richard D. DiMarchi

    Publicerad 2013
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity av Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    Publicerad 2017
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  15. 15
    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism av Piotr Mróz, Brian Finan, Vasily M. Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Pérez–Tilve

    Publicerad 2018
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications av Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    Publicerad 2023
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  17. 17
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity av Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  18. 18
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes av Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  19. 19
    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia

    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia av Joseph R. Chabenne, Maria DiMarchi Chabenne, Yan Zhao, Jay J. Levy, David L. Smiley, Vasily M. Gelfanov, Richard D. DiMarchi

    Publicerad 2014
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice av Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann

    Publicerad 2017
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: